117 results
Page 3 of 6
8-K
EX-99.2
afluo8h
12 Oct 21
Regulation FD Disclosure
7:50am
S-3ASR
d04lr7 54v
3 Sep 21
Automatic shelf registration
4:22pm
8-K
t2u4q 6q64jd
21 Jun 21
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-99.2
cq3itg h2fqac
21 Jun 21
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-99.1
yekba
21 Jun 21
Entry into a Material Definitive Agreement
4:05pm
DEFA14A
mkr7ak 3pappm
28 Apr 21
Additional proxy soliciting materials
7:53am
DEF 14A
jsn l9za3ukusd
28 Apr 21
Definitive proxy
7:51am
8-K
EX-99.2
et5eykv6gf36ee kbyc9
12 Mar 21
Results of Operations and Financial Condition
8:55am
8-K
EX-99.1
cptu1n4tmevyy 6wadh
12 Mar 21
Results of Operations and Financial Condition
8:55am
10-K
2tn4m6z 2umx
12 Mar 21
Annual report
8:46am
8-K
EX-99.1
yy627u3
13 Jan 21
Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients
9:03am
8-K
48vw9
13 Jan 21
Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients
9:03am
8-K
EX-99.2
myfs3n hhtvyld8sbx
5 Jan 21
Inhibrx Announces Phase 1 Dose Escalation Results of
12:00am
8-K
EX-99.1
k46 xtc5b9mds
5 Jan 21
Inhibrx Announces Phase 1 Dose Escalation Results of
12:00am
10-Q
lu7oo2y 6zqhkkzz
13 Nov 20
Quarterly report
4:09pm
8-K
EX-99.1
pe2g je14m2scapm7d
12 Nov 20
Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients
6:07am